Heat Biologics Inc (NASDAQ:HTBX) traded down 30.7% during trading on Wednesday . The stock traded as low as $1.37 and last traded at $1.42. 5,485,197 shares were traded during trading, an increase of 561% from the average session volume of 829,592 shares. The stock had previously closed at $2.05.
Several equities research analysts recently commented on the company. Brookline Cap M reaffirmed a “buy” rating on shares of Heat Biologics in a research report on Wednesday, August 1st. HC Wainwright set a $6.00 price objective on Heat Biologics and gave the company a “buy” rating in a research report on Friday, November 16th. Finally, ValuEngine raised Heat Biologics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.
Heat Biologics (NASDAQ:HTBX) last released its quarterly earnings data on Thursday, November 15th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.05. Heat Biologics had a negative return on equity of 94.53% and a negative net margin of 331.02%. The company had revenue of $1.84 million for the quarter, compared to analysts’ expectations of $1.50 million. As a group, analysts forecast that Heat Biologics Inc will post -1.03 earnings per share for the current fiscal year.
Heat Biologics Company Profile (NASDAQ:HTBX)
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Read More: How to Invest in Marijuana Stocks
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.